Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar;460(3):237-49.
doi: 10.1007/s00428-012-1203-5. Epub 2012 Feb 10.

Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features

Affiliations
Review

Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features

Jaime Prat. Virchows Arch. 2012 Mar.

Abstract

Malignant epithelial tumors (carcinomas) are the most common ovarian cancers and also the most lethal gynecological malignancies. Based on histopathology and molecular genetic alterations, ovarian carcinomas are divided into five main types (high-grade serous (70%), endometrioid (10%), clear cell (10%), mucinous (3%), and low-grade serous carcinomas (<5%)) that account for over 95% of cases. These types are essentially distinct diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, and molecular events during oncogenesis, response to chemotherapy, and prognosis. For a successful specific treatment, reproducible histopathological diagnosis of the tumor cell type is critical. The five tumor types are morphologically diverse and resemble carcinomas of the uterus. Actually, recent investigations have demonstrated that a significant number of cancers, traditionally thought to be primary ovarian tumors (particularly serous, endometrioid, and clear cell carcinomas), originate in the fallopian tube and the endometrium and involve the ovary secondarily. This review summarizes recent advances in the molecular pathology which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.

PubMed Disclaimer

References

    1. J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 - PubMed
    1. Hum Pathol. 2009 Sep;40(9):1213-23 - PubMed
    1. Am J Surg Pathol. 2004 Apr;28(4):496-504 - PubMed
    1. Cancer. 2001 Dec 1;92(11):2829-36 - PubMed
    1. Gynecol Oncol. 1996 Feb;60(2):238-44 - PubMed

LinkOut - more resources